Following the discontinuation in the UK of the only single active praziquantel product for equine tapeworm treatment, BAVP member Prof. Jacqui Matthews from the Moredun Research Institute has teamed up with Westgate Labs and Equisal to produce a guide on best practice for strategic equine endoparasite control.
See Equisal’s press release for more details.
The guide includes reccommended treatment choices based on positive worm egg count and/or tapeworm tests at different times of the year, and a table showing the current anthelmintic resistance status of equine endoparasites.
Prof. Matthews commented in the press release: “I think it’s an issue to limit prescribers’ options for worm species-targeted treatments. Wormer resistance is a growing problem and has the potential to become a major horse welfare threat. Losing the option of a praziquantel-only product means that any treatment option for tapeworm infection will now also impact redworms, whether required or not. Frequent drug exposure speeds the development of resistance and, over time, has potential to significantly decrease the effectiveness of the few chemicals that we have to treat life-threatening worm burdens in horses. To guard against this, we must become more strategic with parasite control. This means seeking tailor-made solutions for control based on knowledge of management, infection risk, drug sensitivity and, importantly, robust diagnostic tests.”